ZMZhenxuan Ma

Zhenxuan Ma

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Zhenxuan Ma has a total of 37 co-authors. Here are the top co-authors by number of shared publications:

  • Jiming Zhang

    Shanghai Key Laboratory of Infectious Diseases and Biosafety Emergency Response, Department of Infectious Diseases, National Medical Center for Infectious Diseases, Huashan Hospital, Fudan University

    3 shared publications
  • Sisi Yang

    Department of Infectious Diseases, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China

    3 shared publications
  • Fahong Li

    Department of Infectious Diseases, Shanghai Key Laboratory of Infectious Diseases and Biosafety Emergency Response, Shanghai Institute of Infectious Diseases and Biosecurity, National Medical Center for Infectious Diseases, Huashan Hospital Fudan University Shanghai China

    2 shared publications
  • Haoxiang Zhu

    Department of Infectious Diseases, Shanghai Key Laboratory of Infectious Diseases and Biosafety Emergency Response, Shanghai Institute of Infectious Diseases and Biosecurity, National Medical Center for Infectious Diseases, Huashan Hospital Fudan University Shanghai China

    2 shared publications
  • Jingjing He

    Department of Infectious Diseases, Shanghai Key Laboratory of Infectious Diseases and Biosafety Emergency Response, Shanghai Institute of Infectious Diseases and Biosecurity, National Medical Center for Infectious Diseases, Huashan Hospital Fudan University Shanghai China

    2 shared publications
  • Qiaofeng Ye

    Department of Biobehavioral Health, Pennsylvania State University, University Park, PA, USA

    2 shared publications

Latest Publications

  • Open Access

    A Body Shape Index Shows Stronger Associations with Falls than BMI among Older Adults: Evidence from the NHATS Cohort

    by Zhenxuan Ma, Indrakshi Roy

    Introduction: Falls are a major public health concern among older adults, leading to injuries, loss of independence, and increased mortality. A body shape index (ABSI), which integrates waist circumference with height and weight, may better characterize abdominal adiposity than body mass index (BMI). To our knowledge, this is the first study to examine the association between ABSI and fall risk in older adults using data from the National Health and Aging Trends Study (NHATS). Methods: We analyzed data from NHATS, a nationally representative cohort of US Medicare beneficiaries aged ≥65 years. Baseline anthropometric data (height, weight, waist circumference) from round 1 were linked to 12-month fall outcomes in round 2. Exposures were BMI and ABSI. Survey-weighted logistic regression models estimated associations between each measure and fall outcomes, adjusting for sociodemographic and health-related covariates. Results: In adjusted models, ABSI was significantly associated with both any fall (odds ratio [OR] = 1.15, 95% confidence interval [CI]: 1.04–1.27; p = 0.009) and multiple falls (OR = 1.20, 95% CI: 1.03–1.39; p = 0.018). BMI showed weaker and less consistent associations (any fall: OR = 1.02, 95% CI: 1.00–1.03; p = 0.030; multiple falls: OR = 1.01, 95% CI: 0.995–1.03; p = 0.158). Associations were stronger among adults aged ≥80 years and those with multimorbidity or conditions such as arthritis, hypertension, or diabetes. Conclusion: ABSI may be a more sensitive anthropometric measure than BMI for identifying older adults at risk for falls, underscoring its potential to improve geriatric fall-risk assessment and prevention strategies.

  • Open Access

    Letter to the editor on “Current burden of steatotic liver disease and fibrosis among adults in the United States, 2017–2023”

    by Sisi Yang, Zhenxuan Ma

    Letter to the Editor on “Current Burden of Steatotic Liver Disease and Fibrosis among Adults in the United States, 2017-2023”

  • Open Access

    Clinical impact of hepatitis delta virus coinfection on liver fibrosis in hepatitis B patients: a population-based study

    by Sisi Yang, Qiaofeng Ye, Yida Yang, Zhenxuan Ma

    Background: Evaluation of liver fibrosis appears to be easily overlooked in the clinic for the chronic Hepatitis D. Herein, we determine the Clinical Impact of liver fibrosis among HBsAg-positive/Anti-HDV positive US general adults. Methods: Data were obtained from the National Health and Nutrition Examination Survey (NHANES) 1999–2020. Liver fibrosis was assessed by the Fibrosis-4 (FIB-4) and aspartate aminotransferase to platelet ratio index (APRI) score. To minimize confounding, propensity score matching (PSM) was applied to compare HBV/HDV-coinfected and HBV-monoinfected individuals. Results: Out of 107,622 NHANES adults, 54,550 were tested for HBsAg and Anti-HDV, of whom 214 were identified as HBsAg-positive only, 50 were identified as HBsAg-positive/Anti-HDV-positive with available data for FIB-4/APRI. Mean APRI scores were 0.26 for the Non-Viral Hepatitis (NVH) group, 0.37 for the HBV group, and 0.42 for the HBV + HDV group. Corresponding mean FIB-4 scores were 1.07, 1.34, and 1.58, respectively. After PSM, HDV-infected individuals exhibited significantly higher fibrosis scores compared to HBV-positive individuals. Conclusion: Hepatitis D is more severe than hepatitis B, with a higher propensity to progress to liver fibrosis. These findings highlight the importance of routine fibrosis screening in HBsAg-positive/anti-HDV-positive individuals to prevent advanced liver disease.


  • Accuracy of International Guidelines in Identifying Normal Liver Histology in Chinese Patients With HBeAg‐Positive Chronic HBV Infection

    by Yidi Jia, Xun Qi, Xueping Yu, Minhui Dong, Jingwen Wu, Jing Li, Jingjing He, Zhenxuan Ma, Xueyun Zhang, Yiran Xie, et al.

    We evaluated the diagnostic accuracy of various international guideline criteria for identifying HBeAg‐positive chronic HBV infection patients with no significant liver disease. A total of 1108 HBeAg‐positive CHB patients were retrospectively enrolled. The guidelines assessed included those from the European Association for the Study of the Liver (EASL) 2017, the American Association for the Study of the Liver Disease (AASLD) 2018, the Asian Pacific Association for the Study of the Liver (APASL) 2015 and the Chinese Society of Hepatology (CSH) 2022. The CSH criteria demonstrated a higher proportion of patients with G0‐1 and S0‐1 (82.9%) compared to the EASL (75.9%), AASLD (75.3%) and APASL groups (58.8%). Additionally, the CSH criteria exhibited a significantly higher predictive value (AUC 0.782, 95% CI 0.754–0.809) than the EASL (AUC 0.765, 95% CI 0.737–0.793), AASLD (AUC 0.749, 95% CI 0.720–0.778) and APASL (AUC 0.720, 95% CI 0.690–0.750) criteria for identifying G0‐1 and S0‐1. Adding quantitative HBsAg levels (> 104 IU/mL) to the EASL, AASLD and APASL criteria improved diagnostic performance. Consequently, the CSH guideline thresholds showed higher accuracy in identifying Chinese HBeAg‐positive patients with no significant liver disease compared to EASL, AASLD and APASL criteria, emphasising the importance of considering quantitative HBsAg in the evaluation of HBeAg‐positive chronic HBV infection.

  • Open Access

    Reduction of Hepatitis B Surface Antigen May Be More Significant in PEGylated Interferon-Alpha Therapy Combined with Nucleotide Analogues than Combined with Nucleoside Analogues in Chronic Hepatitis B Patients: A Propensity Score Matching Study

    by Yiran Xie, Haoxiang Zhu, Yifei Guo, Zhenxuan Ma, Xun Qi, Feifei Yang, Richeng Mao, Jiming Zhang

    Background. Nucleotide analogues (NTs) monotherapy may have a more significant effect on reducing hepatitis B surface antigen (HBsAg) than nucleoside analogues (NSs) due to their immunomodulatory function. However, this superiority remains unknown when combined with PEGylated interferon α (PegIFNα). Therefore, this study aimed to explore whether NTs have more significant antiviral effects than NSs in combination therapy with PegIFNα. Methods. Chronic hepatitis B (CHB) patients treated with PegIFNα plus nucleos(t)ide analogues (NAs) were retrospectively recruited. Efficacy and the predictors of hepatitis B surface antigen (HBsAg) reduction >1 log10 IU/mL after 48 weeks were analyzed. Results. A total of 95 patients were included and divided into the PegIFNα + NTs group and the PegIFNα + NSs group. Propensity score matching (PSM) was performed. The PegIFNα + NTs group had a greater reduction of HBsAg (−3.52 vs. −2.33 log10 IU/mL, ) and a higher proportion of patients with HBsAg reduction >1 log10 IU/mL (100.0% vs. 72.2%, ) even after PSM. However, HBsAg and hepatitis B e-antigen (HBeAg) loss rates, HBeAg seroconversion rates, degree of HBeAg and hepatitis B virus (HBV) DNA decline, HBV DNA undetectable rates, and alanine aminotransferase (ALT) normalization rates showed no significant differences. Subgroup analyses showed the difference in the reduction of HBsAg was particularly evident in HBeAg-positive and the “add-on” subgroups. PegIFNα plus NTs (OR = 36.667, 95% CI = 3.837–350.384) was an independent predictor for HBsAg reduction >1 log10 IU/mL after 48 weeks. Conclusion. This study suggests that PegIFNα plus NTs may lead to more HBsAg reduction, especially in HBeAg-positive and “add-on” patients.


  • Thyroid dysfunction incidence and risk factors in Chinese chronic hepatitis B patients treated with pegylated interferon alpha: A long‐term follow‐up study

    by Zhenxuan Ma, Yanli Qin, Yidi Jia, Yiran Xie, Xun Qi, Yifei Guo, Jingjing He, Yongmei Zhang, Fahong Li, Jie Yu, et al.

    The long‐term impact, incidence and risk factors of thyroid dysfunction in chronic hepatitis B (CHB) patients receiving pegylated interferon (IFN) alpha (PegIFN‐alpha) therapy remain unclear. We aim to investigate the long‐term safety of thyroid dysfunction in CHB patients receiving PegIFN‐alpha. A retrospective observational study of 425 CHB patients with normal baseline thyroid function was carried out. Patients were followed up over 10 years to assess thyroid function after receiving IFN. At the end of the IFN therapy, 67 patients (15.8%) had developed thyroid dysfunction, 31 patients (46.3%) had hyperthyroidism and 64.4% presented with subclinical thyroid dysfunction. In follow‐up of thyroid dysfunction patients, 37 patients (74.0%) spontaneously regained normal thyroid function. Pretreatment thyroid‐stimulating hormone (TSH) level, thyroid peroxidase antibody (TPOAb) positivity and free thyroxine (FT4) were independent risk factors associated with thyroid dysfunction incidence. High TSH level (OR = 9.866, 95%CI, 3.245–29.998) was associated with a greater likelihood of hypothyroidism. High FT4 levels (OR = 0.464, 95%CI, 0.248–0.868) indicate a low likelihood of thyroid dysfunction. Thyroid dysfunction is a common but acceptable side effect of IFN therapy for CHB. Most thyroid dysfunction is reversible. Pretreatment TSH level and TPOAb positivity are risk factors for thyroid dysfunction development during IFN therapy. A high TSH level predicts an increased incidence of hypothyroidism. Moreover, FT4 may be a protective factor for thyroid dysfunction.


  • Open Access

    Adding an Artificial Tail—Anchor to a Peptide-Based HIV-1 Fusion Inhibitor for Improvement of Its Potency and Resistance Profile

    by Shan Su, Zhenxuan Ma, Chen Hua, Weihua Li, Lu Lu, Shibo Jiang

    Peptides derived from the C-terminal heptad repeat (CHR) of human immunodeficiency virus type 1 (HIV-1) envelope protein transmembrane subunit gp41, such as T20 (enfuvirtide), can bind to the N-terminal heptad repeat (NHR) of gp41 and block six-helix bundle (6-HB) formation, thus inhibiting HIV-1 fusion with the target cell. However, clinical application of T20 is limited because of its low potency and genetic barrier to resistance. HP23, the shortest CHR peptide, exhibits better anti-HIV-1 activity than T20, but the HIV-1 strains with E49K mutations in gp41 will become resistant to it. Here, we modified HP23 by extending its C-terminal sequence using six amino acid residues (E6) and adding IDL (Ile-Asp-Leu) to the C-terminus of E6, which is expected to bind to the shallow pocket in the gp41 NHR N-terminal region. The newly designed peptide, designated HP23-E6-IDL, was about 2- to 16-fold more potent than HP23 against a broad spectrum of HIV-1 strains and more than 12-fold more effective against HIV-1 mutants resistant to HP23. These findings suggest that addition of an anchor–tail to the C-terminus of a CHR peptide will allow binding with the pocket in the gp41 NHR that may increase the peptide’s antiviral efficacy and its genetic barrier to resistance.